Switch to:

GuruFocus Financial Strength Rank measures how strong a company’s financial situation is. It is based on these factors

1. The debt burden that the company has as measured by its Interest coverage (current year).
2. Debt to revenue ratio. The lower, the better
3. Altman Z-score.

A company ranks high with financial strength is likely to withstand any business slowdowns and recessions.

Financial Strength : 5/10

vs
industry
vs
history
Cash to Debt 1.75
ISIS's Cash to Debt is ranked lower than
73% of the 860 Companies
in the Global Biotechnology industry.

( Industry Median: 61.94 vs. ISIS: 1.75 )
Ranked among companies with meaningful Cash to Debt only.
ISIS' s 10-Year Cash to Debt Range
Min: 0.24  Med: 1.42 Max: 4.87
Current: 1.75
0.24
4.87
Equity to Asset 0.31
ISIS's Equity to Asset is ranked lower than
84% of the 617 Companies
in the Global Biotechnology industry.

( Industry Median: 0.68 vs. ISIS: 0.31 )
Ranked among companies with meaningful Equity to Asset only.
ISIS' s 10-Year Equity to Asset Range
Min: -0.85  Med: 0.33 Max: 0.76
Current: 0.31
-0.85
0.76
F-Score: 6
Z-Score: 5.45
M-Score: -2.92
GuruFocus Profitability Rank ranks how profitable a company is and how likely the company’s business will stay that way. It is based on these factors:

1. Operating Margin
2. Trend of the Operating Margin (5-year average). The company with an uptrend profit margin has a higher rank.
••3. Consistency of the profitability
4. Piotroski F-Score
5. Predictability Rank•

The maximum rank is 10. A rank of 7 or higher means a higher profitability and may stay that way. A rank of 3 or lower indicates that the company has had trouble to make a profit.

Profitability Rank is not directly related to the Financial Strength Rank. But if a company is consistently profitable, its financial strength will be stronger.

Profitability & Growth : 5/10

vs
industry
vs
history
Operating margin (%) 7.66
ISIS's Operating margin (%) is ranked higher than
76% of the 677 Companies
in the Global Biotechnology industry.

( Industry Median: -71.14 vs. ISIS: 7.66 )
Ranked among companies with meaningful Operating margin (%) only.
ISIS' s 10-Year Operating margin (%) Range
Min: -438.91  Med: -80.37 Max: -12.18
Current: 7.66
-438.91
-12.18
Net-margin (%) 7.47
ISIS's Net-margin (%) is ranked higher than
77% of the 677 Companies
in the Global Biotechnology industry.

( Industry Median: -67.10 vs. ISIS: 7.47 )
Ranked among companies with meaningful Net-margin (%) only.
ISIS' s 10-Year Net-margin (%) Range
Min: -334.33  Med: -102.40 Max: 127.52
Current: 7.47
-334.33
127.52
ROE (%) 7.54
ISIS's ROE (%) is ranked higher than
81% of the 777 Companies
in the Global Biotechnology industry.

( Industry Median: -30.76 vs. ISIS: 7.54 )
Ranked among companies with meaningful ROE (%) only.
ISIS' s 10-Year ROE (%) Range
Min: -280.13  Med: -40.12 Max: 86.43
Current: 7.54
-280.13
86.43
ROA (%) 2.59
ISIS's ROA (%) is ranked higher than
79% of the 866 Companies
in the Global Biotechnology industry.

( Industry Median: -27.09 vs. ISIS: 2.59 )
Ranked among companies with meaningful ROA (%) only.
ISIS' s 10-Year ROA (%) Range
Min: -59.44  Med: -21.74 Max: 25.19
Current: 2.59
-59.44
25.19
ROC (Joel Greenblatt) (%) 39.55
ISIS's ROC (Joel Greenblatt) (%) is ranked higher than
88% of the 838 Companies
in the Global Biotechnology industry.

( Industry Median: -390.34 vs. ISIS: 39.55 )
Ranked among companies with meaningful ROC (Joel Greenblatt) (%) only.
ISIS' s 10-Year ROC (Joel Greenblatt) (%) Range
Min: -800.86  Med: -124.62 Max: -22.1
Current: 39.55
-800.86
-22.1
Revenue Growth (3Y)(%) 22.50
ISIS's Revenue Growth (3Y)(%) is ranked higher than
79% of the 412 Companies
in the Global Biotechnology industry.

( Industry Median: 1.10 vs. ISIS: 22.50 )
Ranked among companies with meaningful Revenue Growth (3Y)(%) only.
ISIS' s 10-Year Revenue Growth (3Y)(%) Range
Min: -39.4  Med: -2.30 Max: 83.7
Current: 22.5
-39.4
83.7
EBITDA Growth (3Y)(%) -30.30
ISIS's EBITDA Growth (3Y)(%) is ranked lower than
81% of the 429 Companies
in the Global Biotechnology industry.

( Industry Median: -4.70 vs. ISIS: -30.30 )
Ranked among companies with meaningful EBITDA Growth (3Y)(%) only.
ISIS' s 10-Year EBITDA Growth (3Y)(%) Range
Min: -49.6  Med: -4.50 Max: 61.3
Current: -30.3
-49.6
61.3
EPS Growth (3Y)(%) -27.00
ISIS's EPS Growth (3Y)(%) is ranked lower than
76% of the 418 Companies
in the Global Biotechnology industry.

( Industry Median: -6.80 vs. ISIS: -27.00 )
Ranked among companies with meaningful EPS Growth (3Y)(%) only.
ISIS' s 10-Year EPS Growth (3Y)(%) Range
Min: -71.2  Med: 2.00 Max: 117.8
Current: -27
-71.2
117.8
» ISIS's 10-Y Financials

Financials


Revenue & Net Income
Cash & Debt
Oprt. Cash Flow & Free Cash Flow

» Details

Guru Trades

Q3 2014

ISIS Guru Trades in Q3 2014

Murray Stahl 17,000 sh (unchged)
» More
Q4 2014

ISIS Guru Trades in Q4 2014

Paul Tudor Jones 6,473 sh (New)
Joel Greenblatt 8,745 sh (New)
Murray Stahl 17,000 sh (unchged)
» More
Q1 2015

ISIS Guru Trades in Q1 2015

Murray Stahl 17,000 sh (unchged)
Paul Tudor Jones 6,390 sh (-1.28%)
Joel Greenblatt 7,892 sh (-9.75%)
» More
Q2 2015

ISIS Guru Trades in Q2 2015

Steven Cohen 140,100 sh (New)
Jim Simons 51,314 sh (New)
Paul Tudor Jones 32,507 sh (+408.72%)
Joel Greenblatt 14,839 sh (+88.03%)
Murray Stahl 17,000 sh (unchged)
» More
» Details

Insider Trades

Latest Guru Trades with ISIS

(List those with share number changes of more than 20%, or impact to portfolio more than 0.1%)

No Entry found in the selected group of Gurus. You can
  • 1. Modify your Personalized List of Gurus, or
  • 2. Click on Premium Premium Tools above to check out all the Gurus, or
  • 3. Click on Premium Plus Premium Plus above for the stocks picks of all the institutional investment advisors (>4000)
» Interactive Charts

Peter Lynch Chart ( What is Peter Lynch Charts )

Ratios

vs
industry
vs
history
P/E(ttm) 277.27
ISIS's P/E(ttm) is ranked lower than
92% of the 220 Companies
in the Global Biotechnology industry.

( Industry Median: 33.70 vs. ISIS: 277.27 )
Ranked among companies with meaningful P/E(ttm) only.
ISIS' s 10-Year P/E(ttm) Range
Min: 5.56  Med: 8.51 Max: 361.48
Current: 277.27
5.56
361.48
PE(NRI) 303.20
ISIS's PE(NRI) is ranked lower than
94% of the 216 Companies
in the Global Biotechnology industry.

( Industry Median: 33.30 vs. ISIS: 303.20 )
Ranked among companies with meaningful PE(NRI) only.
ISIS' s 10-Year PE(NRI) Range
Min: 115  Med: 216.74 Max: 389.12
Current: 303.2
115
389.12
P/B 20.21
ISIS's P/B is ranked lower than
92% of the 747 Companies
in the Global Biotechnology industry.

( Industry Median: 4.11 vs. ISIS: 20.21 )
Ranked among companies with meaningful P/B only.
ISIS' s 10-Year P/B Range
Min: 3  Med: 10.36 Max: 1710
Current: 20.21
3
1710
P/S 19.71
ISIS's P/S is ranked lower than
65% of the 604 Companies
in the Global Biotechnology industry.

( Industry Median: 10.47 vs. ISIS: 19.71 )
Ranked among companies with meaningful P/S only.
ISIS' s 10-Year P/S Range
Min: 4.33  Med: 12.86 Max: 84.47
Current: 19.71
4.33
84.47
PFCF 75.72
ISIS's PFCF is ranked lower than
70% of the 145 Companies
in the Global Biotechnology industry.

( Industry Median: 40.25 vs. ISIS: 75.72 )
Ranked among companies with meaningful PFCF only.
ISIS' s 10-Year PFCF Range
Min: 3.7  Med: 33.79 Max: 198.35
Current: 75.72
3.7
198.35
POCF 65.88
ISIS's POCF is ranked lower than
77% of the 202 Companies
in the Global Biotechnology industry.

( Industry Median: 32.50 vs. ISIS: 65.88 )
Ranked among companies with meaningful POCF only.
ISIS' s 10-Year POCF Range
Min: 3.54  Med: 37.88 Max: 1473
Current: 65.88
3.54
1473
EV-to-EBIT 144.41
ISIS's EV-to-EBIT is ranked lower than
88% of the 235 Companies
in the Global Biotechnology industry.

( Industry Median: 26.88 vs. ISIS: 144.41 )
Ranked among companies with meaningful EV-to-EBIT only.
ISIS' s 10-Year EV-to-EBIT Range
Min: -311.1  Med: -14.10 Max: 596.9
Current: 144.41
-311.1
596.9
PEG 40.97
ISIS's PEG is ranked lower than
94% of the 77 Companies
in the Global Biotechnology industry.

( Industry Median: 2.22 vs. ISIS: 40.97 )
Ranked among companies with meaningful PEG only.
ISIS' s 10-Year PEG Range
Min: 0  Med: 0.52 Max: 9959.5
Current: 40.97
0
9959.5
Current Ratio 8.38
ISIS's Current Ratio is ranked higher than
70% of the 837 Companies
in the Global Biotechnology industry.

( Industry Median: 4.14 vs. ISIS: 8.38 )
Ranked among companies with meaningful Current Ratio only.
ISIS' s 10-Year Current Ratio Range
Min: 2.49  Med: 4.76 Max: 9.89
Current: 8.38
2.49
9.89
Quick Ratio 8.31
ISIS's Quick Ratio is ranked higher than
71% of the 837 Companies
in the Global Biotechnology industry.

( Industry Median: 4.00 vs. ISIS: 8.31 )
Ranked among companies with meaningful Quick Ratio only.
ISIS' s 10-Year Quick Ratio Range
Min: 2.49  Med: 4.71 Max: 9.89
Current: 8.31
2.49
9.89
Days Sales Outstanding 3.82
ISIS's Days Sales Outstanding is ranked higher than
95% of the 570 Companies
in the Global Biotechnology industry.

( Industry Median: 62.77 vs. ISIS: 3.82 )
Ranked among companies with meaningful Days Sales Outstanding only.
ISIS' s 10-Year Days Sales Outstanding Range
Min: 1.87  Med: 32.71 Max: 86.04
Current: 3.82
1.87
86.04

Valuation & Return

vs
industry
vs
history
Price/Net Cash 42.03
ISIS's Price/Net Cash is ranked lower than
92% of the 451 Companies
in the Global Biotechnology industry.

( Industry Median: 7.88 vs. ISIS: 42.03 )
Ranked among companies with meaningful Price/Net Cash only.
ISIS' s 10-Year Price/Net Cash Range
Min: 4.75  Med: 23.46 Max: 489.77
Current: 42.03
4.75
489.77
Price/Net Current Asset Value 32.50
ISIS's Price/Net Current Asset Value is ranked lower than
91% of the 540 Companies
in the Global Biotechnology industry.

( Industry Median: 6.84 vs. ISIS: 32.50 )
Ranked among companies with meaningful Price/Net Current Asset Value only.
ISIS' s 10-Year Price/Net Current Asset Value Range
Min: 4.49  Med: 15.37 Max: 705.5
Current: 32.5
4.49
705.5
Price/Tangible Book 20.92
ISIS's Price/Tangible Book is ranked lower than
89% of the 690 Companies
in the Global Biotechnology industry.

( Industry Median: 5.33 vs. ISIS: 20.92 )
Ranked among companies with meaningful Price/Tangible Book only.
ISIS' s 10-Year Price/Tangible Book Range
Min: 2.82  Med: 9.05 Max: 216.67
Current: 20.92
2.82
216.67
Price/Median PS Value 1.48
ISIS's Price/Median PS Value is ranked lower than
69% of the 542 Companies
in the Global Biotechnology industry.

( Industry Median: 1.07 vs. ISIS: 1.48 )
Ranked among companies with meaningful Price/Median PS Value only.
ISIS' s 10-Year Price/Median PS Value Range
Min: 0.2  Med: 0.94 Max: 5.02
Current: 1.48
0.2
5.02
Price/Graham Number 15.28
ISIS's Price/Graham Number is ranked lower than
95% of the 173 Companies
in the Global Biotechnology industry.

( Industry Median: 3.26 vs. ISIS: 15.28 )
Ranked among companies with meaningful Price/Graham Number only.
ISIS' s 10-Year Price/Graham Number Range
Min: 1.12  Med: 1.54 Max: 20.65
Current: 15.28
1.12
20.65
Earnings Yield (Greenblatt) (%) 0.73
ISIS's Earnings Yield (Greenblatt) (%) is ranked higher than
75% of the 823 Companies
in the Global Biotechnology industry.

( Industry Median: -6.10 vs. ISIS: 0.73 )
Ranked among companies with meaningful Earnings Yield (Greenblatt) (%) only.
ISIS' s 10-Year Earnings Yield (Greenblatt) (%) Range
Min: 0.2  Med: 0.30 Max: 0.76
Current: 0.73
0.2
0.76

Analyst Estimate

Dec15 Dec16
Revenue(Mil) 285 383
EPS($) -0.28 -0.29
EPS without NRI($) -0.28 -0.29

Business Description

Industry: Biotechnology » Biotechnology
Compare:NVO, AMGN, GILD, BIIB, CELG » details
Traded in other countries:ISIS.Switzerland, 0R0N.UK, ISI.Germany,
Isis Pharmaceuticals Inc was incorporated in California in 1989, and in January 1991 the Company changed its state of incorporation to Delaware. The Company is engaged in antisense drug discovery and development, exploiting a novel drug discovery platform it created to generate a pipeline of first-in-class drugs. Antisense technology provides a direct route from genomics to drugs. The Company business segments are Drug Discovery and Development operations. Its flagship product, KYNAMRO (mipomersen sodium) injection, is on the market in the United States for patients with homozygous familial hypercholesterolemia, or HoFH. Patients with HoFH are at high cardiovascular risk and cannot reduce their low-density lipoprotein cholesterol, or LDL-C, sufficiently with currently available lipid-lowering therapies. The Company has a pipeline of 31 drugs in development. Company's ISIS-TTR and ISIS-SMN drugs are in late stage development. Its partners include Biogen Idec, AstraZeneca and Roche. The Company's drugs compete with existing therapies for market share. It also competes with specialized pharmaceutical firms and large pharmaceutical companies acting either independently or together with biopharmaceutical companies. The Company is subject to regulation under the Occupational Safety and Health Act, the Toxic Substances Control Act, the Resource Conservation and Recovery Act and other present and potential future federal, state and local regulations.
» More Articles for ISIS

Headlines

Articles On GuruFocus.com
buffet May 31 2015 
buffet May 31 2015 
Bayer Enters Into Collaboration With Isis For Enhancing Its Drug Portfolio May 07 2015 
Analysts Provide Update for Biogen, PTC Therapeutics, GW Pharma, and Isis Pharma Apr 22 2015 
Value vs. Growth: Is Jim Cramer Right about ISIS Pharmaceuticals? Dec 13 2014 
Weekly CEO Sells Highlight: Keynote Systems Inc., Isis Pharmaceuticals, Coleman Cable Inc. Jul 01 2013 
Isis Pharmaceuticals Inc. (ISIS) Director, COO B Lynne Parshall sells 17,200 Shares Dec 29 2010 
Isis Pharmaceuticals Inc. (ISIS) Chairman, President, CEO Stanley T Crooke sells 32,000 Shares Dec 29 2010 
Isis Pharmaceuticals Inc. Reports Operating Results (10-Q) Nov 05 2010 
Isis Pharmaceuticals Inc. Reports Operating Results (10-Q) May 07 2010 

More From Other Websites
AstraZeneca and Isis Pharmaceuticals to discover and develop antisense drugs for cardiovascular,... Aug 20 2015
Regeneron Leads and Shire Dragged the Large-Cap Stocks Aug 19 2015
Zeltia SA Earnings Q2*, 2015 Aug 13 2015
5 Top BioPharma Stocks That May Have Sold Off Too Much and Become Bargains Aug 12 2015
ISIS PHARMACEUTICALS INC Financials Aug 11 2015
10-Q for Isis Pharmaceuticals, Inc. Aug 08 2015
ISIS PHARMACEUTICALS INC Files SEC form 10-Q, Quarterly Report Aug 05 2015
Edited Transcript of ISIS earnings conference call or presentation 4-Aug-15 3:30pm GMT Aug 04 2015
Isis Pharmaceuticals (ISIS) Misses Earnings Estimates in Q2 - Tale of the Tape Aug 04 2015
Isis Reports Financial Results And Highlights For Second Quarter 2015 Aug 04 2015
Isis beats 2Q profit forecasts Aug 04 2015
Isis beats 2Q profit forecasts Aug 04 2015
ISIS PHARMACEUTICALS INC Files SEC form 8-K, Results of Operations and Financial Condition,... Aug 04 2015
Isis Reports Financial Results And Highlights For Second Quarter 2015 Aug 04 2015
Q2 2015 Isis Pharmaceuticals Inc Earnings Release - Before Market Open Aug 04 2015
Isis Reports Positive Data from KYNAMRO® (mipomersen sodium) FOCUS FH Phase 3 Study in Patients... Aug 03 2015
Isis Reports Positive Data from KYNAMRO® (mipomersen sodium) FOCUS FH Phase 3 Study in Patients... Aug 03 2015
Will Isis Pharmaceuticals (ISIS) Beat Q2 Earnings Estimates? - Analyst Blog Aug 03 2015
Isis Pharma 8-K Filing Shows Company Enters Agreement with Astrazeneca To Discover And Develop... Aug 03 2015

Personalized Checklist

Checklist has been moved to "Checklist" tab.

Get WordPress Plugins for easy affiliate links on Stock Tickers and Guru Names | Earn affiliate commissions by embedding GuruFocus Charts
GuruFocus Affiliate Program: Earn up to $400 per referral. ( Learn More)
FEEDBACK